TB-500
Thymosin Beta-4 (Synthetic Fragment)
Systemic healing and anti-inflammatory signaling
How it works
TB-500 upregulates actin, the protein that forms the cytoskeleton of cells. By modulating actin polymerization, it promotes cell migration, differentiation, and tissue remodeling. It also downregulates inflammatory cytokines.
What the research explores
In published research, TB-500 has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.
- Accelerates wound healing across multiple tissue types
- Reduces systemic and local inflammation
- Promotes new blood vessel formation
- Supports cardiac tissue repair
- Enhances muscle flexibility and reduces injury risk
- Stimulates stem cell proliferation
Thymosin Beta-4 has reached Phase II clinical trials for wound healing and myocardial infarction repair, representing the most clinically advanced healing peptide.
Adverse events & gaps
Favorable safety profile in clinical trials. Some reports of mild administration-site reactions.
Stay Informed on
Peptide Research
Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.
No spam. Unsubscribe at any time.